ARD:肺分子特征的综合分析揭示了系统性硬化症相关间质性肺病的关键驱动因素

2022-01-31 MedSci原创 MedSci原创

肺组织的综合转录组分析揭示了 SSc-ILD 中纤维化的关键特征。基于网络的贝叶斯方法提供了对适用于治疗 SSc-ILD 的关键调控基因和分子靶点的深入见解。

  目的:肺纤维化,也称为间质性肺病(ILD),发生在超过一半的系统性硬化症(SSc患者中,并且是SSc 相关死亡率三分之一的死亡原因,目前尚无有效的治疗方式。该研究分析了系统性硬化症相关间质性肺病 (SSc-ILD) 的转录组数据,以评估与相关肺部疾病相关的显著分子和细胞特征,并确定疾病模块中的关键驱动基因和靶分子。

     方法:来自 SSc-ILD (n=52)、特发性肺纤维化 (IPF) (n=549)、非特异性间质性肺炎 (n=49) 和肺动脉高压 (n=81) 和来自正常健康对照(n = 331)的差异表达基因被过滤、进行功能富集分析、基于网络的关键驱动分析和基于内核的扩散评分。在 SSc-ILD 患者中评估了富集的通路与临床参数之间的关联性。

     结果:SSc-ILD 与其他纤维化肺部疾病具有共同的关键致病途径,但在某些病理过程中是可区分的。 SSc-ILD 在分子和细胞特征上与 IPF大致相似,但肌成纤维细胞的信号更强,在 SSc-ILD中肌成纤维细胞处于衰老和抗凋亡状态。 p53信号通路是SSc-ILD肺组织和肺成纤维细胞中最丰富的信号通路,与肺一氧化碳扩散能力、细胞衰老和凋亡显著相关。 EEF2EFF2KPHKG2VCAM1PRKACBITGA4CDK1CDK2FN1 HDAC1 是疾病模块中具有高扩散评分的关键调节因子。 

    结论:肺组织的综合转录组分析揭示了 SSc-ILD 中纤维化的关键特征。基于网络的贝叶斯方法提供了对适用于治疗 SSc-ILD 的关键调控基因和分子靶点的深入见解。关键驱动基因在肺纤维化中起重要作用,能控制 SSc-ILD 的疾病模块,但它们都还不是当前治疗的直接靶点。 

 

出处:

Jung SM, Park K, Kim K. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease. Annals of the Rheumatic Diseases 2022;81:108-116.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
    2022-10-17 amy0559
  4. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2028396, encodeId=7acb20283969a, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Nov 13 06:52:01 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815860, encodeId=013b181586047, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sun Feb 27 18:52:01 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671986, encodeId=209916e1986dd, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Mon Oct 17 01:52:01 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771456, encodeId=594d1e714563d, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Thu Jun 09 00:52:01 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983219, encodeId=78191983219e4, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Nov 28 22:52:01 CST 2022, time=2022-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017339, encodeId=2659201e3399c, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jun 18 12:52:01 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627408, encodeId=eb7c162e4084b, content=<a href='/topic/show?id=dbcee69217e' target=_blank style='color:#2F92EE;'>#系统性硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76921, encryptionId=dbcee69217e, topicName=系统性硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf521117287, createdName=yhy100207, createdTime=Fri Jan 28 01:52:01 CST 2022, time=2022-01-28, status=1, ipAttribution=)]

相关资讯

Arthritis Rheumatol:系统性硬化症患者的舒张功能障碍的危险因素和对死亡率的影响

DD与SSc患者死亡风险增加独立相关。医务人员应在SSc患者中解决潜在的可改变危险因素,包括CAD和肥胖症,以降低患者死亡风险。

Autoimmun Rev:静脉注射免疫球蛋白可有效改善系统性硬化症的皮肤受累情况

静脉注射免疫球蛋白(IVIG)是系统性硬化症SSc的一种新治疗方法。据推测,IVIG具有免疫调节和抗纤维化的活性。IVIG通常具有良好的耐受性,副作用很少。

ARD:抗纤维化因子KLF4在真皮成纤维细胞中被miR-10/TFAP2A/TBX5轴抑制

KLF4在系统性硬化症(SSc)的皮肤成纤维细胞中具有抗纤维化作用,其表达受到TmiR-10/TFAP2A/TBX5轴的抑制。

A&R:可溶性CD146的多种变异与系统性硬化症有关:一种新型促纤维化因子的鉴定

sCD146的变异体,特别是新的I5-13-sCD146剪接变体可以构成用于诊断和治疗系统性硬化症 (SSc)以及其他血管生成或纤维化相关病理的新生物标志物和/或分子靶标。

Lancet Rheumatology: 硬皮病患者为中心的干预网络 (SPIN) 队列中的疼痛水平和相关因素:一项多中心横断面研究

疼痛在系统性硬化症患者中很常见。控制社会人口学变量后,更大的疼痛与多种系统性硬化症相关的症状有关,包括关节挛缩、手指溃疡、胃肠道受累、皮肤受累和重叠综合征的存在。

结缔组织疾病中的肺动脉高压:新证据?新挑战?

肺动脉高压是系统性硬化症、混合性结缔组织病和系统性红斑狼疮等不同结缔组织疾病的致命并发症。